Track Sarepta Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Sarepta Therapeutics, Inc. SRPT · Stock Open Sarepta Therapeutics, Inc. in new tab

16.07 USD
P/E
803.50
EPS
0.02
P/B
1.13
ROE
-8.05
Beta
0.45
Target Price
21.77 USD
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

🧾 Earnings Recap – Q1 2026

Shares fell 4.5% after the earnings release as investors reacted negatively to cautious ELEVIDYS growth commentary and a reiterated full-year guidance range that lacked upward revision amid ongoing commercial ramp challenges.

  • Total net product revenue reached $331 million, including $229 million from PMO therapies and $102 million from ELEVIDYS.
  • Management emphasized stabilization of marketed products but highlighted the gradual path from patient consideration to infusion for ELEVIDYS.
  • Full-year ELEVIDYS revenue guidance was reiterated at $1.2 billion to $1.4 billion, signaling no acceleration despite evidence of clinical benefit.
  • Financial position remains solid, with approximately $748 million in cash and investments and positive GAAP and non-GAAP earnings.
  • Pipeline progress continues, especially with siRNA programs in DM1, FSHD, and Huntington’s disease, although meaningful impacts remain on the horizon.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
P/E803.50
EPS0.02
Book Value14.26
Price to Book1.13
Debt/Equity70.58
% Insiders5.931%
Growth
Revenue Growth-0.05%
Earnings Growth26.64%
Estimates
Forward P/E10.83
Forward EPS1.48
Target Mean Price21.77

DCF valuation

Model fair value for Sarepta Therapeutics, Inc. (SRPT)
Result
Sign in to run the valuation for SRPT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
22 analysts · consensus Hold · mean target 21.77 USD (low 5.00, high 38.00) · as of 15 Nov 2026
Low 5.00
Mean 21.77
High 38.00
Price 16.07
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Sarepta Therapeutics, Inc. Logo Sarepta Therapeutics, Inc. Analysis (SRPT)

United States Health Care Official Website Stock

Is Sarepta Therapeutics, Inc. a good investment? Sarepta Therapeutics, Inc. (SRPT) is currently trading at 16.07 USD. Market analysts have a consensus price target of 21.77 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 803.50. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Sarepta Therapeutics, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is 1.48.

Investor FAQ

Does Sarepta Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of 0.02.

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
NMS (United States) SRPT
FRA (Germany) AB3A.F
SAO (Brazil) S1RP34.SA
LSE (United Kingdom) 0L35.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 12, 2012 1:6
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion